Evidence map›Paper›PMID 42062795›Full record

ArticlePharmacology research & perspectives2026

Kaempferol Improves Alzheimer's Disease by Inhibiting Neuronal Ferroptosis via Activating GPX4/AKR1C3 Signaling Pathway.

Le Li, Manying Yang, Jiale Tao, Yonghong Zhao, Na Zhao, Shiguo Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Investigation of the Potential Neuroprotective Mechanisms ofInternational journal of molecular sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Le LiCollege of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, China.
Manying YangKey Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Department of Pharmacology, Shihezi University, Shihezi, Xinjiang, China.
Jiale TaoKey Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Department of Pharmacology, Shihezi University, Shihezi, Xinjiang, China.
Yonghong ZhaoKey Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Department of Pharmacology, Shihezi University, Shihezi, Xinjiang, China.
Na ZhaoKey Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Department of Pharmacology, Shihezi University, Shihezi, Xinjiang, China.
Shiguo SunCollege of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, China.ORCID https://orcid.org/0000-0003-3135-8542

Funding

Corps Guiding Science and Technology Projects 2022ZD050Scientific and technological research projects in key fields of the Corps 2025DA013
6 · The paper itself

Abstract

Kaempferol has been shown to be beneficial in the treatment of Alzheimer's disease (AD) in animal models. However, the action mechanism remains unclear. AKR1B1 has been identified as a target of kaempferol, initially suggested by the Therapeutic Target Database, DrugBank, and PubChem, and subsequently confirmed through experimental validation. Kaempferol treatment facilitated the expression of AKR1B1 in PC12 cells exposed to Aβ

Indexed as

Alzheimer DiseaseKaempferolsNeuroprotective AgentsAldehyde ReductaseAldo-Keto ReductasesAmyloid beta-PeptidesAnimalsDisease Models, AnimalHumansMaleMice, Inbred C57BLNeuronsNF-E2-Related Factor 2PC12 CellsPeptide FragmentsPeroxidasesAkr1b3 protein, mouseAldehyde ReductaseAldo-Keto ReductasesAmyloid beta-Peptidesamyloid beta-protein (1-42)glutathione peroxidase 4, mousekaempferolKaempferolsNeuroprotective AgentsNF-E2-Related Factor 2Peptide FragmentsPeroxidasesphospholipid hydroperoxide cysteine peroxidasePhospholipid Hydroperoxide Glutathione PeroxidaseSuperoxide DismutaseAKR1C3aldo‐keto reductase family 1 member B1Alzheimer's diseaseKaempferolneuronal ferroptosis

Identifiers

PMID42062795
PMCPMC13132798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.